A Guide to Early Drug Discovery

• Introduction Mohammed Shahid; Preface; Modern drug discovery: factors shaping the current and future landscape Mohammed Shahid, James Baker and Jayashree Aiyar; Part I. Drug Target: Linking Fundamental Biology to Disease Mohammed Shahid, M. Emani, G. Starling, J. Aiyar: 1. Target identification and preclinical validation Kati Räsänen; 2. The impact of translational biomarkers on drug discovery and development Donald Apanovitch and William Cairns; 3. Translational animal models: lessons from psychiatric disease Jennifer Fletcher, Ben Grayson and Michael Harte; 4. Quantitative systems biology and pharmacology Jess Wu, Tomoki Yoneyama and Dean BottinoI; 5. Flourishing landscape of therapeutic categories: how to select and characterize drug modalities Jerome Hochman; Part II. Discovery and Early Development of Small Molecule Drug Candidates Mohammed Shahid and J. Aiyar: 6. From classical to innovative screening approaches: bridging the gap to efficiently discover chemical starting points Benjamin Bader, Volker Badock, Jörg Weiske, Martina Schäfer, Anselm Schneider, Vera Pütter, Simon Holton, Martin Lange and Holger Steuber; 7. New developments in medicinal chemistry approaches for drug candidate identification Leena Otsomaa and Olli Tormakangas; 8. Application and impact of generative artificial intelligence in early drug discovery Cheng Fang and Torsten Herbertz; Part III. Discovery and Early Development of Biologics G. Starling and Emani; 9. Advances in therapeutic antibody discovery: from in vivo to in vitro and beyond Lei Chen, Jane Seagal and Chung-Ming Hsieh; 10. Creation of biologics therapeutics with drug-like properties – design, optimization, and developability Laurence Fayadat-Dilman; 11. Next generation biologics – multi-specifics, antibody drug conjugates and drugging difficult targets Rebecca Chen, Zhiping Jiang, Haili Zhang, Fan Yang and Javier Chaparro-Riggers; 12. Living cells as therapeutics Gary Starling; Part IV. Preclinical Adme and Safety J. Baker: 13. The evolution of small molecule pk optimisation Simon Taylor, Barry Jones and James Baker; 14. Therapeutic proteins – pk design considerations Sher Karki, Nicole Rodriguez, Panida Lertkiatmongkol and Shelley Sims Belouski; 15. Gene therapy – what is the role of DMPK in this modality? Guanrong Huang, Shobha Purushothama and Stephen Wang; 16. The application of translational PKPD modelling in drug discovery James W. T. Yates; 17. Pharmaceutical development across modalities in drug discovery Courtney David, Jing Ling and Olivier Mozziconacci; 18. Approaches to identify safe drugs across modalities Claudette L. Fuller, Lisa M. Plitnick and Alan H. Stokes; Part V. External Innovation Shahid Mohammed and Jayashree Aiyer: 19. Drug discovery and the benefit of public private partnerships, a solution to drive innovation in women's health? Marcel van Duin; 20. Governmental initiatives to boost progress and industry output: impact of the innovative medicines initiative Elisabetta Vaudano and Hugh Laverty; 21. Inventions to application: power of knowledge transfer Jack Findlay and Anji Milleri; 22. Harnessing innovation and delivering added value: view from the biotech venture capital world Sham Nikan and Narayanan 'Suri' Surendranb; 23. The evolution and future prospects of the contract research organisation (CRO) sector Brian McFerran and Stuart McElroy; Glossary and Index.

Select Guide Rating